Healthcare
Live Price
Offline$189.90
-1.35% today
Window Change
+42.83%
Window
Jun 23, 2025 โ Apr 6, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 198 bars ยท Jun 23, 2025 โ Apr 6, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
AstraZeneca PLC (AZNCF) is a Healthcare stock with a market cap of $294.40B. The stock last traded around $189.90 and up 42.8% across the available one-year price window (Jun 23, 2025 โ Apr 6, 2026). Baseline metrics include revenue growth of +8.6%, EPS growth of +45.4%, a dividend yield of 1.8%. What stands out right now is revenue +8.6%, EPS +45.4%, free cash flow +19.2% with operating margin 23.5% and ROIC 12.9%. The dividend is present but secondary, with a yield around 1.8%. Valuation sits in the middle of the pack at P/E 26.9 and price/sales 4.6. Stock Foundry combines AZNCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.6% vs +7.6% peer median
Operating Margin
Above sector median
+23.5% vs +19.4% peer median
P/E
Below sector median
26.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Feb 10, 2026 with revenue ahead of estimates by +0.4%.
The operating story is still moving forward
Revenue is running at +8.6% and EPS at +45.4%, with operating margin around 23.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.8%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.3% over the next 5 trading days and finished higher after 2 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 10, 2026 | โ | +5.9% | +7.9% | -0.0% |
2025 Nov 6, 2025 | -29.3% | -1.7% | +5.0% | +6.2% |
2025 Jul 29, 2025 | -27.3% | +3.4% | -0.1% | +6.5% |
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
AZNCF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
AZNCF Max Drawdown
-12.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for AZNCF and SPY.
Company Overview
AstraZeneca PLC
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.